argenx SE operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares argenx SE with three other
miscellaneous service companies in Europe:
GW Pharmaceuticals PLC
of the United Kingdom
(2018
sales of £20.00 million [US$26.05 million]
of which 100%
was Novel Therapeutics),
MDxHealth S.A.
(24.10 million Euro [US$26.17 million]
of which 100%
was Diagnostic Tools), and
Oncodesign Sa
which is
based in France
(20.09 million Euro [US$21.81 million]
).
Sales Analysis.
argenx SE reported sales of 21.48 million Euro (US$23.32 million)
for the
year ending
December of 2018.
This
represents
a
sharp
decrease of 41.0%
versus 2017, when the company's sales were 36.42 million Euro.
Contributing to the drop in overall sales was the 78.7% decline
in Research and Development Service Fees (F, from 6.60 million Euro to 1.41 million Euro.
There were also decreases in sales in
Upfront Payments (down 57.1% to 8.64 million Euro)
.
However, these declines were partially offset by the increase in sales of
Milestone Payments (up 18.2% to 11.44 million Euro)
.